167 related articles for article (PubMed ID: 24685306)
1. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Li W; Ren S; Li J; Li A; Fan L; Li X; Zhao C; He Y; Gao G; Chen X; Li S; Shi J; Zhou C; Fei K; Schmid-Bindert G
Lung Cancer; 2014 Jun; 84(3):295-300. PubMed ID: 24685306
[TBL] [Abstract][Full Text] [Related]
2. Correlation Analysis between T790M Status and Clinical Characteristics of Patients with EGFR-sensitive Mutation Advanced NSCLC who Progressed after the First Generation and First-line EGFR-TKIs Administration: A Real-world Exploratory Study.
Zhen Y; Xu YB; Deng RY; Li M; Ma MT; Zhou ZG; Meng QJ; Gong YN; Zhao LY; Liu YB
Comb Chem High Throughput Screen; 2024; 27(6):845-853. PubMed ID: 37282652
[TBL] [Abstract][Full Text] [Related]
3. Brain-Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis.
Fan Y; Wang X; Yang C; Chen H; Wang H; Wang X; Hou S; Wang L; Luo Y; Sha X; Yang H; Yu T; Jiang X
J Magn Reson Imaging; 2023 Dec; 58(6):1838-1847. PubMed ID: 37144750
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of SSEA-4 on TKI-resistant non-small cell lung cancer with EGFR-T790M mutation.
Chen NY; Lin CW; Lai TY; Wu CY; Liao PC; Hsu TL; Wong CH
Proc Natl Acad Sci U S A; 2024 Jan; 121(5):e2313397121. PubMed ID: 38252815
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.
Oxnard GR; Arcila ME; Sima CS; Riely GJ; Chmielecki J; Kris MG; Pao W; Ladanyi M; Miller VA
Clin Cancer Res; 2011 Mar; 17(6):1616-22. PubMed ID: 21135146
[TBL] [Abstract][Full Text] [Related]
6. Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?
Califano R; Romanidou O; Mountzios G; Landi L; Cappuzzo F; Blackhall F
Drugs; 2016 May; 76(8):831-40. PubMed ID: 27129321
[TBL] [Abstract][Full Text] [Related]
7. Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?
Kim S; Kim SH; Kim J; Kim MH; Lee MK; Eom JS
Cancer Res Treat; 2023 Oct; 55(4):1190-1197. PubMed ID: 37080607
[TBL] [Abstract][Full Text] [Related]
8. Apatinib added when NSCLC patients get slow progression with EGFR-TKI: A prospective, single-arm study.
Liu M; Li X; Zhang H; Ren F; Liu J; Li Y; Dong M; Zhao H; Xu S; Liu H; Chen J
Cancer Med; 2023 Dec; 12(24):21735-21741. PubMed ID: 38033095
[TBL] [Abstract][Full Text] [Related]
9. Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients.
Jiang T; Li A; Su C; Li X; Zhao C; Ren S; Zhou C; Zhang J
Oncotarget; 2017 Sep; 8(37):62648-62657. PubMed ID: 28977977
[TBL] [Abstract][Full Text] [Related]
10. Survival Analysis of 159 Patients With Advanced Non-Small-Cell Lung Cancer Resistant to First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.
Hu A; Li K; Zheng H; Rao H; Zhang T; Li B
Clin Med Insights Oncol; 2023; 17():11795549231176398. PubMed ID: 37378392
[TBL] [Abstract][Full Text] [Related]
11. A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor.
Zhao J; Feng HH; Zhao JY; Liu LC; Xie FF; Xu Y; Chen MJ; Zhong W; Li LY; Wang HP; Zhang LI; Xiao YI; Chen WJ; Wang MZ
Oncol Lett; 2016 Apr; 11(4):2573-2579. PubMed ID: 27073519
[TBL] [Abstract][Full Text] [Related]
12. Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.
Wang Y; Guo Z; Li Y; Zhou Q
Open Med (Wars); 2016; 11(1):68-77. PubMed ID: 28352770
[TBL] [Abstract][Full Text] [Related]
13. CT Radiomics Predict EGFR-T790M Resistance Mutation in Advanced Non-Small Cell Lung Cancer Patients After Progression on First-line EGFR-TKI.
Tang X; Li Y; Shen LT; Yan WF; Qian WL; Yang ZG
Acad Radiol; 2023 Nov; 30(11):2574-2587. PubMed ID: 36941156
[TBL] [Abstract][Full Text] [Related]
14. Author Correction: Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Hayes TK; Aquilanti E; Persky NS; Yang X; Kim EE; Brenan L; Goodale AB; Alan D; Sharpe T; Shue RE; Westlake L; Golomb L; Silverman BR; Morris MD; Fisher TR; Beyene E; Li YY; Cherniack AD; Piccioni F; Hicks JK; Chi AS; Cahill DP; Dietrich J; Batchelor TT; Root DE; Johannessen CM; Meyerson M
Nat Commun; 2024 Apr; 15(1):3273. PubMed ID: 38627431
[No Abstract] [Full Text] [Related]
15. EGFR, EGFR TKI, and EMSI: a never-ending story.
Kim YC
Transl Lung Cancer Res; 2014 Dec; 3(6):365-7. PubMed ID: 25806321
[No Abstract] [Full Text] [Related]
16. Development, growth, and beyond.
Persson PB; Bondke Persson A
Acta Physiol (Oxf); 2023 Apr; 237(4):e13955. PubMed ID: 36815460
[No Abstract] [Full Text] [Related]
17. 2020 and Beyond.
Blackie M; Czerwiec MK
Lit Med; 2022; 40(2):229-234. PubMed ID: 38661882
[No Abstract] [Full Text] [Related]
18. Beyond "Can we?".
Dimitrov K; Jain SK; Olson APJ
J Hosp Med; 2024 Jan; 19(1):75-76. PubMed ID: 37792420
[No Abstract] [Full Text] [Related]
19. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
20. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W
Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
